About Eaton Vance Ohio Municipal Income Trust (EVO)
Eaton Vance Ohio Municipal Income Trust is a closed-end management investment company that primarily focuses on providing current income for investors through the acquisition and management of a diversified portfolio of municipal securities. These securities are predominantly issued by Ohio municipalities and are designed to generate tax-exempt income for investors. The Trust aims to offer a blend of capital appreciation and income through strategic investments, while also considering the potential impact of market interest rates and economic conditions on municipal debt. By focusing on Ohio-based issuers, the Trust seeks to capitalize on local market opportunities and provide value to its shareholders. Read More
Group revenues of € 535.1 m ((7.1)%); Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD business
Transaction showcases Evotec's unique capability enabling customers to produce biologics faster and at lower costs through its continuous manufacturing technology
HAMBURG, DE / ACCESS Newswire / October 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its interim statement for the first nine months 2025 on Wednesday, 05 November 2025.
HAMBURG, DE / ACCESS Newswire / August 6, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will announce its half-year interim report for the first six months of 2025 on Wednesday, 13 August 2025.
HAMBURG, DE / ACCESS Newswire / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU in Toulouse, France, for a consideration of about US$ 300 m in cash. In addition, the planned transaction terms include further technology related consideration, future development revenues, milestones and product royalties.
Successful execution of new strategy for sustainable and profitable growth leading to changing revenue mix with strong demand for Evotec's differentiated platforms
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that it has updated its revenue guidance for the fiscal year 2025. Guidance on R&D expenses and adjusted EBITDA remains unchanged.
NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK
Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.
